Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Fluence Corporation Limited (ASX:FLC)

ABN

52 127 734 196

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Class of +securities issued or to be issued

Ordinary Shares

89,030,295

- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- 4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

Fully paid Ordinary shares issued in a private placement to professional or sophisticated investors or to other investors that did not require a disclosure document the Corporations Act 2001 (Cth)

Yes

(If issued as consideration for growing global demand and generate fun			
6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Issued under a private placement to growing global demand and generate fur sales growth, general working capital and or associated with the private placement 6a Is the entity an *eligible entity holder approval under rule 7.1A? Yes 6a Is the entity an *eligible entity holder approval under rule 7.1A? Yes 6a Is the entity an *eligible entity holder approval under rule 7.1A? Yes 6a Is the entity an *eligible entity holder approval under rule 7.1A? Yes 6a Is the entity an *eligible entity holder approval under rule 7.1A? Yes 6b The date the security holder resolution under rule 7.1A was passed 24 May 2018 6c Number of *securities issued without security holder approval under rule 7.1 43,686,816 6d Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval under rule 7.3, or another specific security holder approval Nil		 not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or 	
(If issued as consideration for the acquisition of assets, clearly identify those assets) growing global demand and generate fur sales growth, general working capital and a associated with the private placement 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? Yes 6a Is the entity an *eligible entity holder approval under rule 7.1A? Yes 6a Is the entity an *eligible entity holder approval under rule 7.1A? Yes 6a Is the entity an *eligible entity holder approval under rule 7.1A was passed Yes 6b The date the security holder approval under rule 7.1A was passed 24 May 2018 6c Number of *securities issued with security holder approval under rule 7.1A 43,686,816 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval under rule 7.3, or another specific security holder approval under rule 7.3, or another specific security holder approval under rule 7.3, or another specific security holder approval under rule 7.3, or another specific security holder approval under rule 7.3, or another specific security holder approval under rule 7.3, or another specific security holder approval under rule 7.4 Nil	5	Issue price or consideration	A\$0.37 per ordinary share
 that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval under rule 7.1A 6e Number of *securities issued with security holder approval under rule 7.1A 6e Number of *securities issued with security holder approval under rule 7.1A 	6	(If issued as consideration for the acquisition of assets, clearly	Issued under a private placement to fund growing global demand and generate further sales growth, general working capital and costs associated with the private placement
 resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval under rule 7.1A 6e Number of *securities issued with security holder approval under rule 7.1A 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval 	6a	that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the +securities the</i> <i>subject of this Appendix 3B</i> , and	Yes
 without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval under rule 7.1A 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval 	6b	resolution under rule 7.1A was	24 May 2018
 with security holder approval under rule 7.1A Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval 	6с	without security holder approval	45,343,479
with security holder approval under rule 7.3, or another specific security holder approval	6d	with security holder approval	43,686,816
	6e	with security holder approval under rule 7.3, or another specific security holder approval	Nil

⁺ See chapter 19 for defined terms.

- 6f Number of +securities issued Nil under an exception in rule 7.2
- 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- 6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to **ASX Market Announcements**
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

- 8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)
- Number and +class of all 9 +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
525,898,461	Fully Paid Ordinary Shares

Number and +Class		
Number	Number Class – Fully Paid Ordinary	
	Shares	
	Escrow Expiry Date	
Not applicable	Not applicable	
Total Fully Paid Ordinary Shares on issue		
Total Fully Pa	id Ordinary Shares on issue	
	id Ordinary Shares on issue red and unquoted)	
	'	
, (quot	'	
(quot 525,898,461	'	

The issue price of A\$0.37 represented a discount of 16% to the 15-day VWAP of A\$0.44 prior to the trading halt on 26 October 2018. The VWAP period started on 5 October 2018 and ended on 25 October 2018. Source of VWAP: IRESS

Not applicable

7.1 - 19,436,746 7.1A - NIL

5 November 2018

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged

Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable.
12	Is the issue renounceable or non- renounceable?	Not applicable.
13	Ratio in which the ⁺ securities will be offered	Not applicable.
14	⁺ Class of ⁺ securities to which the offer relates	Not applicable.
15	⁺ Record date to determine entitlements	Not applicable.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable.
17	Policy for deciding entitlements in relation to fractions	Not applicable.
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with.	Not applicable.
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	Not applicable.
20	Names of any underwriters	Not applicable.
21	Amount of any underwriting fee or commission	Not applicable.

⁺ See chapter 19 for defined terms.

22	Names of any brokers to the issue	Not applicable.
23	Fee or commission payable to the broker to the issue	Not applicable.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable.
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable.
28	Date rights trading will begin (if applicable)	Not applicable.
29	Date rights trading will end (if applicable)	Not applicable.
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable.
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable.
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable.
33	⁺ Issue date	Not applicable.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of ⁺securities (*tick one*)
- (a) +Securities described in Part 1

(b) All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

Entities that have ticked box 34(b)

- 38 Number of ⁺securities for which ⁺quotation is sought
 - of ⁺securities for which
- 39 ⁺Class of ⁺securities for which quotation is sought

³⁷ A copy of any trust deed for the additional +securities

⁺ See chapter 19 for defined terms.

40 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional ⁺securities do not rank equally, please state:

- (a) the date from which they do
- (b) the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- (c) the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another ⁺security, clearly identify that other ⁺security)

42 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in clause 38)

Number	+Class

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *+*securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

1	
C	

Sign here:

Date: 5 November 2018

Company Secretary Fluence Corporation Limited Ross Kennedy

Print name:

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	392,648,167
 Add the following: Number of fully paid ⁺ordinary securities 	44,219,999
 issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with 	
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil
"A"	436,868,166

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	65,530,225	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	46,093,479	
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	46,093,479	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	65,530,225	
Note: number must be same as shown in Step 2		
Subtract "C"	46,093,479	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	19,436,746	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	43,686,816	
Step 3: Calculate "E", the amount of 7.1A that has already been used	43,686,816	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	43,686,816	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	43,686,816	
Note: number must be same as shown in Step 2		
Subtract "E"	43,686,816	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	NIL [Note: this is the remaining placement capacity under rule 7.1A]	

⁺ See chapter 19 for defined terms.

Appendix 3D – Schedule 1			
Number		Class – Unlisted Options	
		Exercise Price	Expiration Date
	2,000,000	\$0.30	18 Dec 2018
	2,000,000	\$0.40	18 Dec 2019
	1,940,000	\$0.40	31 Jan 2019
	500,000	\$0.35	13 Apr 2020
	431,473	\$0.30	23 Dec 2019
	431,473	\$0.40	23 Dec 2019
	100,000	\$0.30	28 Feb 2020
	100,000	\$0.40	28 Feb 2020
	75,000	\$0.30	23 Mar 2020
	75,000	\$0.40	23 Mar 2020
	50,000	\$0.30	12 Apr 2020
	50,000	\$0.40	12 Apr 2020
	400,000	\$0.5909	16 May 2020
	100,000	\$0.5909	28 May 2020
	1,000,000	\$0.40	18 May 2020
	1,000,000	\$0.40	18 May 2021
	1,000,000	\$0.933	31 May 2020
	250,000	\$0.7926	25 July 2020
	325,000	\$0.867	25 August 2020
	200,000	\$1.00	25 September 2020
	350,000	\$1.071	26 October 2020
	500,000	\$0.74	31 October 2020
	200,000	\$1.00	9 November 2020
	350,000	\$1.00	9 February 2021
	75,000	\$0.872	20 December 2020
	25,000	\$0.84	10 January 2021
	1,000,000	\$0.817	4 March 2021
	2,000,000	\$0.72	31 March 2019
	1,000,000	\$0.72	31 March 2019
	175,000	\$0.86	3 May 2021
	11,191,336	\$0.93	25 May 2025
	447,389	\$0.85	25 May 2025
	3,850,000	\$1.20	13 July 2021
	3,850,000	\$1.50	13 July 2021
	1,500,000	\$0.835	13 July 2021
	350,000	\$0.835	25 May 2025
	300,000	\$0.72	14 July 2019
	100,000	\$0.97	6 July 2021
	750,000	\$0.75	30 September 2019
	1,140,000	\$0.86	13 November 2021
	4,604,000	\$0.81	12 September 2021
	180,000	\$0.58	11 March 2022
	1,375,000	\$0.477	25 May 2022
	500,000	\$0.457	27 August 2022
	750,000	\$1.20	31 July 2022
	750,000	\$1.50	31 July 2022
			,
	49,240,671	Total Unlisted Options	

Appendix 3B – Schedule 1

⁺ See chapter 19 for defined terms.